| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 383.025 | 314.637 | 374.893 | 467.292 | 473.837 | 449.365 | 713.683 | 983.310 | 474.717 | 539.652 |
| Total Income - EUR | 383.250 | 314.792 | 379.166 | 467.829 | 477.608 | 452.915 | 716.689 | 993.752 | 498.855 | 564.649 |
| Total Expenses - EUR | 285.894 | 236.975 | 290.102 | 369.307 | 389.669 | 366.867 | 558.086 | 583.493 | 397.333 | 458.533 |
| Gross Profit/Loss - EUR | 97.356 | 77.817 | 89.064 | 98.522 | 87.939 | 86.048 | 158.603 | 410.259 | 101.521 | 106.116 |
| Net Profit/Loss - EUR | 81.491 | 65.047 | 85.268 | 93.846 | 83.164 | 81.552 | 151.436 | 401.026 | 97.281 | 91.951 |
| Employees | 6 | 6 | 0 | 7 | 0 | 7 | 7 | 7 | 5 | 5 |
Check the financial reports for the company - Dovexim Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 4.842 | 3.511 | 7.515 | 6.417 | 4.206 | 22.936 | 37.104 | 32.140 | 51.022 | 224.497 |
| Current Assets | 193.598 | 212.133 | 278.702 | 347.599 | 457.946 | 513.841 | 615.106 | 1.113.908 | 1.080.801 | 807.989 |
| Inventories | 23.107 | 23.623 | 40.913 | 40.061 | 42.953 | 36.157 | 70.436 | 52.736 | 60.736 | 43.440 |
| Receivables | 96.205 | 70.661 | 61.359 | 116.520 | 55.044 | 46.776 | 129.571 | 275.807 | 74.681 | 92.781 |
| Cash | 74.286 | 117.849 | 176.430 | 191.017 | 359.950 | 430.908 | 415.099 | 785.365 | 945.385 | 671.767 |
| Shareholders Funds | 153.536 | 114.089 | 197.427 | 287.650 | 359.983 | 429.190 | 536.582 | 806.630 | 901.466 | 762.799 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 44.903 | 101.555 | 88.790 | 66.367 | 102.169 | 107.587 | 115.627 | 339.417 | 230.357 | 269.687 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2511 - 2511" | |||||||||
| CAEN Financial Year |
2511
|
|||||||||
Comments - Dovexim Srl